Showing 7631-7640 of 8649 results for "".
- JPM: How did Pfizer Up its COVID-19 Vaccine Capacity? ‘Out of the Box Manufacturing,’ CEO Sayshttps://modernod.com/news/jpm-how-did-pfizer-up-its-covid-19-vaccine-capacity-out-of-the-box-manufacturing-ceo-says/2478757/Earlier this week, Pfizer partner BioNTech upped the pair’s 2021 COVID-19 output projection to 2 billion doses for 2021, up from a previous estimate of 1.3 billion. But how will the companies get there? By doing things “very differently and very out of the box in manufacturing,” CEO Albert Bourla
- CVP Welcomes Three New Ophthalmology Partner Practiceshttps://modernod.com/news/cvp-welcomes-three-new-ophthalmology-partner-practices/2478760/CVP has expanded its platform in the Midwest and Mid-Atlantic regions by adding three partner practices: Columbus Ophthalmology Associates (COA), Valley Eye Institute, near Dayton, Ohio; and Virginia Beach Eye Center. CVP now includes a network of nine partner pra
- Glaukos’ iDose TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 24 Months in Phase 2b Studyhttps://modernod.com/news/glaukos-idose-tr-demonstrates-sustained-iop-reduction-and-favorable-safety-profile-over-24-months-in-phase-2b-study/2478753/Glaukos announced that its iDose TR sustained-release travoprost implant continued to provide sustained substantial reductions in IOP in a 24-month interim analysis of the ongoing 36-month phase 2b clinical trial conducted under a U.S. investigational new drug (IND) protocol. Administered
- US IDE Trial Results for Glaukos’ iStent infinite Show Reduction in IOPhttps://modernod.com/news/us-ide-trial-results-for-glaukos-istent-infinite-show-reduction-in-iop/2478754/Glaukos announced that 12-month U.S. Investigational Device Exemption (IDE) pivotal trial data showed that its iStent infinite Trabecular Micro-Bypass System achieved a substantial reduction in mean diurnal IOP in patients with open-angle glaucoma uncontrolled by prior surgical or medical therapy
- Johnson & Johnson Vision Releases New Guide to Help Slow the Progression of Myopia in Childrenhttps://modernod.com/news/johnson-johnson-vision-releases-new-guide-to-help-slow-the-progression-of-myopia-in-children/2478750/Johnson & Johnson Vision announced a new guide with recommendations for eye care professionals to assess, monitor and treat myopia in children. The guide, titled “Managing Myopia: A Clinical Response to the Growing Epidemic,” is a result of a year of collaboration with lead
- Heidelberg Engineering Names New Clinical Directorhttps://modernod.com/news/heidelberg-engineering-names-new-clinical-director/2478749/Steve Thomson has joined Heidelberg Engineering as Clinical Director to further strengthen the anterior segment product development team, according to a company news release. He will concentrate
- EnChroma Names Vision Industry Veteran Erik Ritchie as CEOhttps://modernod.com/news/enchroma-names-vision-industry-veteran-erik-ritchie-as-ceo/2478743/EnChroma, creators of EnChroma eyewear for color blindness, named Erik Ritchie as its CEO. Mr. Ritchie brings 25 years of experience in the optical industry and other fields. Most recently, he served as Chief Commercial Officer for Zenni Optical, the largest online provider of prescription eyewea
- Ocular Therapeutix Promotes Michael Goldstein, MD, MBA, to President, Ophthalmologyhttps://modernod.com/news/ocular-therapeutix-promotes-michael-goldstein-md-mba-to-president-ophthalmology/2478733/Ocular Therapeutix announced the promotion of Michael Goldstein, MD, MBA, to the newly created position of President, Ophthalmology. Dr. Goldstein will continue to report to Antony Mattessich, Ocular’s President and Chief Executive Officer. With this promotion, Dr. Goldstein will be responsible f
- ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10https://modernod.com/news/proqr-completes-enrollment-of-its-pivotal-trial-of-sepofarsen-for-the-treatment-of-lca10/2478728/ProQR Therapeutics announced it has completed patient enrollment in its phase 2/3 Illuminate study of sepofarsen for the treatment of Leber Congenital Amaurosis 10 (LCA10) due to the p.Cys998X mutation in the CEP290 gene. With enrollment completed, topline results are expected in the first half (
- Ocuphire Completes Enrollment in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol for Reversal of Mydriasishttps://modernod.com/news/ocuphire-completes-enrollment-in-mira-2-phase-3-clinical-trial-investigating-nyxol-for-reversal-of-mydriasis/2478719/Ocuphire Pharma announced that it has completed enrollment earlier than expected in its MIRA-2 phase 3 registration clinical trial evaluating the safety and efficacy of Nyxol to reverse pharmacologically-induced mydriasis. “We are pleased to exceed our enrollment target and reach this impo